Anti-EGFLA/ EGFLAM/ AGRINL functional antibody

Anti-EGFLA/ EGFLAM/ AGRINL functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to EGFLAM/EGFLAM products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0169-Ab-1/ GM-Tg-hg-SE0169-Ab-2Anti-Human EGFLAM monoclonal antibodyHuman
GM-Tg-rg-SE0169-Ab-1/ GM-Tg-rg-SE0169-Ab-2Anti-Rat EGFLAM monoclonal antibodyRat
GM-Tg-mg-SE0169-Ab-1/ GM-Tg-mg-SE0169-Ab-2Anti-Mouse EGFLAM monoclonal antibodyMouse
GM-Tg-cynog-SE0169-Ab-1/ GM-Tg-cynog-SE0169-Ab-2Anti-Cynomolgus/ Rhesus macaque EGFLAM monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0169-Ab-1/ GM-Tg-felg-SE0169-Ab-2Anti-Feline EGFLAM monoclonal antibodyFeline
GM-Tg-cang-SE0169-Ab-1/ GM-Tg-cang-SE0169-Ab-2Anti-Canine EGFLAM monoclonal antibodyCanine
GM-Tg-bovg-SE0169-Ab-1/ GM-Tg-bovg-SE0169-Ab-2Anti-Bovine EGFLAM monoclonal antibodyBovine
GM-Tg-equg-SE0169-Ab-1/ GM-Tg-equg-SE0169-Ab-2Anti-Equine EGFLAM monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0169-Ab-1/ GM-Tg-hg-SE0169-Ab-2; GM-Tg-rg-SE0169-Ab-1/ GM-Tg-rg-SE0169-Ab-2;
GM-Tg-mg-SE0169-Ab-1/ GM-Tg-mg-SE0169-Ab-2; GM-Tg-cynog-SE0169-Ab-1/ GM-Tg-cynog-SE0169-Ab-2;
GM-Tg-felg-SE0169-Ab-1/ GM-Tg-felg-SE0169-Ab-2; GM-Tg-cang-SE0169-Ab-1/ GM-Tg-cang-SE0169-Ab-2;
GM-Tg-bovg-SE0169-Ab-1/ GM-Tg-bovg-SE0169-Ab-2; GM-Tg-equg-SE0169-Ab-1/ GM-Tg-equg-SE0169-Ab-2
Products NameAnti-EGFLAM monoclonal antibody
Formatmab
Target NameEGFLAM
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-EGFLAM benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0169-Ag-1Recombinant multi-species EGFLA/ EGFLAM/ AGRINL protein


    Target information

    Target IDGM-SE0169
    Target NameEGFLAM
    Gene ID133584,268780,365691,693314,479359,101097453,534427,100053309
    Gene Symbol and Synonyms5930412K08,AGRINL,AGRNL,EGFLAM,PIKA,RGD1306592
    Uniprot AccessionQ63HQ2,B4F785,A3KN33
    Uniprot Entry NameEGFLA_HUMAN,EGFLA_RAT,EGFLA_BOVIN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000164318
    Target ClassificationN/A

    The target: EGFLAM, gene name: EGFLAM, also named as AGRINL, AGRNL, PIKA. Predicted to enable calcium ion binding activity and glycosaminoglycan binding activity. Predicted to be involved in animal organ morphogenesis and tissue development. Predicted to act upstream of or within extracellular matrix organization; peptide cross-linking via chondroitin 4-sulfate glycosaminoglycan; and positive regulation of cell-substrate adhesion. Part of cell surface. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.